Clinical Trials Browser

Phase 1/2 × INDUSTRY × duvelisib × Clear all

NCT02391545 2023-09-28

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Phase 1/2 Terminated

55 enrolled 13 charts

Lymphoma, Follicular

NCT04193293 2023-09-21

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05508659 2022-08-19

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Advanced Solid Tumors